Published in Virus Weekly, September 8th, 1997
The decision was based on recent data from clinical trials using Zerit in adults and children which demonstrate that combinations that include d4T can reduce viral load, often to undetectable levels, and increase the body's infection-fighting CD4 cells. Both are proven markers of disease improvement.
Zerit has been available in the U.S. since June 1994 and in Europe since May 1996, and is available in several other countries...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.